Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2017 - 06 - 21

Menarini Ricerche to present the most recent data about the pre-clinical development of its novel ADC MEN1309/OBT076 at the 29th Pezcoller Symposium

Pomezia, June 21, 2017Menarini Ricerche and the UK company Oxford BioTherapeutics (OBT) will present the latest data about their novel antibody drug-conjugate (ADC) MEN1309/OBT076, in development for solid and haematological tumors, at the 29th Pezcoller Symposium which will take place on June 22,23 2017 in Trento, Italy.

Results of the preclinical studies of the novel ADC, as well as the characterization of its target antigen Ly75/CD205, will be summarized in a poster entitled: “MEN1309/OBT076: a novel Antibody-Drug Conjugate targeting the Ly75/CD205 antigen”.

The poster will focus on the antitumor activity of MEN1309/OBT076 in vitro and in vivo. Indeed, MEN1309/OBT076 showed impressive anti-tumoral activity against NHL and triple negative breast cancer cell lines, in the corresponding xenograft models and in Patient-Derived Xenograft (PDX) models.


About MEN1309/OBT076

MEN1309/OBT076 is a fully humanized IgG1 monoclonal antibody conjugated to a potent cytotoxic maytansinoid toxin via a cleavable linker. The ADC is directed against a type I transmembrane glycoprotein and a C-type lectin receptor Ly75/ CD205, that is over-expressed in several solid tumors and non-Hodgking lymphomas (NHL).